Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 4/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172324 | 0.90 | AR (0.48) | ARPARP1MEN1KMT2ANR3C1 | |
| SCHEMBL4183825 | 0.90 | AR (0.48) | ARPARP1NR3C1PGR | |
| SCHEMBL4173001 | 0.87 | AR (0.53) | ARNR3C1PGR | |
| SCHEMBL4182692 | 0.86 | AR (0.44) | ARPARP1 | |
| SCHEMBL4170279 | 0.86 | AR (0.52) | ARNR3C1PGR | |
| SCHEMBL4173608 | 0.83 | AR (0.48) | ARMEN1KMT2ANR3C1PGR | |
| SCHEMBL4186335 | 0.82 | AR (0.48) | ARNR3C1PGR | |
| SCHEMBL13697667 | 0.81 | AR (0.55) | ARNR3C1PGR | |
| SCHEMBL4178975 | 0.81 | AR (0.51) | ARNR3C1PGR | |
| SCHEMBL4182448 | 0.80 | AR (0.53) | ARNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | claimed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | AR 1/4885PARP1 3170/4885MEN1 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.